Cited by 202Meta-analysis and systematic reviewsPharmaceutical industry and healthcareStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 191 of the 192 references it cites were found in a registry or an index.

Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials: A Systematic Review and Meta-Analysis

Rief, Winfried, Nestoriuc, Yvonne, von Lilienfeld-Toal, Anna, Dogan, Imis, Schreiber, Franziska, Hofmann, Stefan G., Barsky, Arthur J., Avorn, Jerry·2009·Drug Safety

DOI 10.2165/11316580-000000000-00000

Open this paper in CoChat — free account

Abstract

Background Biases in adverse effect reporting in randomized controlled trials (RCTs) [e.g. due to investigator expectations or assessment quality] can be quantified by studying the rates of adverse events reported in the placebo arms of such trials.Objective We compared the rates of adverse effects reported in the placebo arms of tricyclic antidepressant (TCA) trials and placebo arms of selective serotonin reuptake inhibitor (SSRI) trials.Methods We conducted a literature search for RCTs across PUBMED, Scopus and the Cochrane Central Register of Controlled Trials (CENTRAL). Only studies allowing adverse effect analysis were included. Publication year ranged from 1981 to 2007.Results Our systematic review and meta-analysis included 143 placebocontrolled RCTs and data from 12,742 patients. Only 21% of studies used structured and systematic adverse effect ascertainment strategies. The way in which trials recorded adverse events influenced the rate of adverse effects substantially. Systematic assessment led to higher rates than less systematic assessment. Far more adverse effects were reported in TCA-placebo groups compared with SSRI-placebo groups, e.g. dry mouth (odds ratio [OR] = 3.5; 95% CI 2.9, 4.2); drowsiness (OR = 2.7; 95%CI 2.2, 3.4); constipation (OR= 2.7; 95%CI 2.1, 3.6); sexual problems (OR =2.3; 95%CI 1.5, 3.5). Regression analyses controlling for various influencing factors confirmed the results.Conclusion Adverse effect profiles reported in clinical trials are strongly influenced by expectations from investigators and patients. This difference cannot be attributed to ascertainment methods. Adverse effect patterns of the drug group are closely related to adverse effects of the placebo group. These results question the validity of the assumption that adverse effects in placebo groups reflect the 'drug-unspecific effects'.

Integrity signals

Registry

Crossref · 10.2165/11316580-000000000-00000

Cites

191 of 191 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.292.7.807 · Cited by 1,735
Experimenter Effects in Behavioral Research
McGuigan, F. J., & Rosenthal, R. (1968) · The American Journal of Psychology · doi:10.2307/1420816 · Cited by 1,633
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Cognitive-Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents With Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.292.16.1969 · Cited by 1,107
Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive–compulsive disorder
Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., Huppert, J. D., Kjernisted, K., Rowan, V., Schmidt, A. B., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.151 · Cited by 1,048
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“Although the pooling of studies is the typical way to analyse general (side) effects,([184,185]) pooling can be problematic.”
Background
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
Self-citation
Efficacy and Safety of Sertraline Treatment of Posttraumatic Stress Disorder
Brady, K. T., Pearlstein, T. B., Asnis, G. M., Baker, D. G., ROTHBAUM, B. O., Sikes, C. R., & Farfel, G. M. (2000) · JAMA · doi:10.1001/jama.283.14.1837 · Cited by 707
Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
Lespérance, F., Frasure-Smith, N., Koszycki, D., Laliberté, M.-A., van Zyl, L. T., Baker, B., Swenson, J. R., Ghatavi, K., Abramson, B. L., Dorian, P., et al. (2007) · JAMA · doi:10.1001/jama.297.4.367 · Cited by 658
When words are painful: unraveling the mechanisms of the nocebo effect
Benedetti, F., Lanotte, M., Lopiano, L., & Colloca, L. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.020 · Cited by 636
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., Longis, P. D., Caputo, S. L., Narciso, P., Pauluzzi, S., Carosi, G., et al. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200112150-00006 · Cited by 473
Multicenter, Double-blind Comparison of Sertraline and Placebo in the Treatment of Posttraumatic Stress Disorder
Davidson, J. R. T., Rothbaum, B. O., van der Kolk, B. A., Sikes, C. R., & Farfel, G. M. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.485 · Cited by 470
Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder
March, J. S., Biederman, J., Wolkow, R., Safferman, A. Z., Mardekian, J., Cook, E. H., Cutler, N. R., Dominguez, R., Ferguson, J. M., Müller, B., et al. (1998) · JAMA · doi:10.1001/jama.280.20.1752 · Cited by 460
How prior experience shapes placebo analgesia
Colloca, L., & Benedetti, F. (2006) · Pain · doi:10.1016/j.pain.2006.04.005 · Cited by 443
The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect
Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2947-06.2006 · Cited by 419
Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia
Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · cited 1×
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
Background
Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder Two Randomized Controlled Trials
Wagner, K. D. (2003) · JAMA · doi:10.1001/jama.290.8.1033 · Cited by 413
The role of learning in nocebo and placebo effects
Colloca, L., Sigaudo, M., & Benedetti, F. (2008) · Pain · doi:10.1016/j.pain.2008.02.006 · Cited by 411
Fluvoxamine for Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Controlled, Multicenter Trial
Riddle, M. A., Reeve, E. A., Yaryura-Tobias, J. A., Yang, H.-M., Claghorn, J. L., Gaffney, G., Greist, J. H., Holland, D., McConville, B. J., Pigott, T. A., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00017 · Cited by 398
Treating Depression in Alzheimer Disease: Efficacy and Safety of Sertraline Therapy, and the Benefits of Depression Reduction: The DIADS
Lyketsos, C. G., DelCampo, L., Steinberg, M., Miles, Q., Steele, C. D., Munro, C., Baker, A. S., Sheppard, J.-M. E., Frangakis, C., Brandt, J., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.737 · Cited by 398
Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder
(1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320054008 · Cited by 384
Fluoxetine for the Treatment of Childhood Anxiety Disorders
Birmaher, B. B., Axelson, D., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., Bridge, J. A., Heo, J., & Brent, D. A. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000037049.04952.9f · Cited by 378
The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients
Vase, L., Robinson, M. E., Verne, N. G., & Price, D. D. (2003) · Pain · doi:10.1016/s0304-3959(03)00073-3 · Cited by 377
Medication Adherence and Persistence as the Cornerstone of Effective Antihypertensive Therapy
Burnier, M. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.04.006 · Cited by 356
Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
Burke, W. J., Gergel, I. P., & Bose, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0410 · Cited by 354
Treatment of Posttraumatic Stress Disorder With Amitriptyline and Placebo
Davidson, J. R. T. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150059010 · Cited by 350
Paroxetine Treatment of Generalized Social Phobia (Social Anxiety Disorder)
Stein, M. B., Liebowitz, M. R., Lydiard, R. B., Pitts, C. D., Bushnell, W., & Gergel, I. P. (1998) · JAMA · doi:10.1001/jama.280.8.708 · Cited by 348
Fluoxetine in post-traumatic stress disorder
Davidson, J. R. T., Roth, S., & Newman, E. (1991) · Journal of Traumatic Stress · doi:10.1007/bf00974559 · Cited by 347
Clomipramine Hydrochloride in Childhood and Adolescent Obsessive-Compulsive Disorder—a Multicenter Trial
DeVeaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D. P., FONTAINE, R., Greist, J. H., Reichler, R. J., Katz, R. J., & Landau, P. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00008 · Cited by 345
Somatization Symptoms and Hypochondriacal Features in the General Population
Rief, W., Hessel, A., & Braehler, E. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00012 · Cited by 339
Self-citation
Double-Blind, Crossover Trial of Fluoxetine and Placebo in Children and Adolescents with Obsessive-Compulsive Disorder
Riddle, M. A., Scahill, L. D., King, R. A., Hardin, M. T., Anderson, G. M., Ort, S. I., SMITH, J., Leckman, J. F., & Cohen, D. J. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199211000-00011 · Cited by 339
Paroxetine in the Treatment of Chronic Posttraumatic Stress Disorder
Tucker, P. M., Zaninelli, R., Yehuda, R., Ruggiero, L., Dillingham, K., & Pitts, C. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1105 · Cited by 324
Placebo-Controlled Trial of Sertraline in the Treatment of Children With Generalized Anxiety Disorder
Rynn, M. A., Siqueland, L., & Rickels, K. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2008 · Cited by 318
Fluoxetine Treatment for Obsessive-Compulsive Disorder in Children and Adolescents: A Placebo-Controlled Clinical Trial
GELLER, D. A., HOOG, S. L., Heiligenstein, J. H., Ricardi, R. K., Tamura, R., KLUSZYNSKI, S., Jacobson, J. G., & FLUOXETINE PEDIATRIC OCD STUDY TEAM (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00011 · Cited by 317
A Multicenter Investigation of Fixed-Dose Fluoxetine in the Treatment of Obsessive-compulsive Disorder
Tollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314
Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients
Price, D. D., Craggs, J. G., Verne, G. N., Perlstein, W. M., & Robinson, M. E. (2006) · Pain · doi:10.1016/j.pain.2006.08.001 · Cited by 271
Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine
van Vliet, I. M., den Boer, J. A., & Westenberg, H. G. M. (1994) · Psychopharmacology · doi:10.1007/bf02244762 · Cited by 270
Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study
Stein, M. B., Fyer, A. J., Davidson, J. R. T., Pollack, M. H., & Wiita, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.756 · Cited by 263
Somatization in the population: from mild bodily misperceptions to disabling symptoms
Hiller, W., Rief, W., & Brähler, E. (2006) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-006-0082-y · Cited by 261
Self-citation
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Fluoxetine in Early Poststroke Depression
Wiart, L., Petit, H., Joseph, P.-A., Mazaux, J., & Barat, M. (2000) · Stroke · doi:10.1161/01.str.31.8.1829 · Cited by 259
A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard‐Andersen, L., Gylding‐Sabroe, J., Kristensen, M., Refsum, H. ‐., Öfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258
Fluoxetine versus other types of pharmacotherapy for depression
Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004185.pub3 · Cited by 255
Efficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
Strik, J. J. M. H., Honig, A., Lousberg, R. L., Lousberg, A., Cheriex, E. C., Tuynman-Qua, H. G., Kuijpers, P. M. J. C., Wellens, H. J. J., & van Praag, H. M. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200011000-00007 · Cited by 255
Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Paroxetine in social phobia/social anxiety disorder
Baldwin, D. S., Bobes, J., Stein, D. J., Scharwächter, I., & Ml, F. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.2.120 · Cited by 252
Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.
Trindade, E. M., Menon, D., Topfer, L.-A., & Coloma, C. (1998) · Europe PMC (PubMed Central) · Cited by 250
Paroxetine in the Treatment of Generalized Anxiety Disorder
Pollack, M. H., Zaninelli, R., Goddard, A. W., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0508 · Cited by 246
Clomipramine in obsessive-compulsive disorder
Katz, R. J., DeVeaugh-Geiss, J., & Landau, P. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90408-t · Cited by 245
Double-blind Parallel Comparison of Three Dosages of Sertraline and Placebo in Outpatients With Obsessive-compulsive Disorder
Greist, J. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160039008 · Cited by 243
A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial ofParoxetine in Children and Adolescents With Social Anxiety Disorder
Wagner, K. D., Berard, R., Stein, M. B., Wetherhold, E., Carpenter, D. J., Perera, P., Gee, M., Davy, K., & Machin, A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1153 · Cited by 240
Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide
Benedetti, F., Amanzio, M., Casadio, C., Oliaro, A., & Maggi, G. (1997) · Pain · doi:10.1016/s0304-3959(97)03346-0 · Cited by 238
Escitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care
Wade, A. G., Lemming, O. M., & Hedegaard, K. B. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200205000-00001 · Cited by 232
Paroxetine Treatment in Children and Adolescents With Obsessive-Compulsive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
GELLER, D. A., Wagner, K. D., Emslie, G. J., Murphy, T. K., CARPENTER, D. J., Wetherhold, E., Perera, P., Machin, A., & GARDINER, C. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000138356.29099.f1 · Cited by 230
Reconsidering the role of personality in placebo effects: Dispositional optimism, situational expectations, and the placebo response
Geers, A. L., Helfer, S. G., Kosbab, K., Weiland, P. E., & Landry, S. J. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2004.08.011 · Cited by 225
Sertraline Treatment of Generalized Social Phobia: A 20-Week, Double-Blind, Placebo-Controlled Study
Ameringen, M. A. V., Lane, R. M., Walker, J. R., Bowen, R. C., Chokka, P. R., Goldner, E. M., Johnston, D. G., Lavallée, Y.-J., Nandy, S., Pecknold, J. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.275 · Cited by 221
Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia
Blomhoff, S., Haug, T. T., Hellström, K., Holme, I., Humble, M. B., Madsbu, H.-P., & Wold, J. E. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.1.23 · Cited by 220
Double-Blind Placebo-Controlled Pilot Study of Sertraline in Military Veterans With Posttraumatic Stress Disorder
Zohar, J., Amital, D., Miodownik, C., Kotler, M., Bleich, A., Lane, R. M., & Austin, C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00013 · Cited by 218
Double-Blind, Fixed-Dose, Placebo-Controlled Study of Paroxetine in the Treatment of Panic Disorder
Ballenger, J. C., Wheadon, D. E., Steiner, M., Bushnell, W., & Gergel, I. P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.36 · Cited by 217
Fluoxetine Versus Placebo in Posttraumatic Stress Disorder
Martényi, F., Brown, E. B., Zhang, H., Prakash, A., & Koke, S. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0305 · Cited by 215
A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression
Wagner, K. D., Jonas, J. M., Findling, R. L., Ventura, D., & Saikali, K. G. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000192250.38400.9e · Cited by 210
Imipramine Treatment of Children with Separation Anxiety Disorder
KLEIN, R. G., KOPLEWICZ, H. S., & KANNER, A. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00005 · Cited by 201
Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study
Rickels, K., Zaninelli, R., McCafferty, J. P., Bellew, K. M., Iyengar, M. K., & Sheehan, D. V. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.749 · Cited by 201
Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart Disease
Veith, R. C., Raskind, M. A., Caldwell, J. H., Barnes, R., Gumbrecht, G., & Ritchie, J. L. (1982) · New England Journal of Medicine · doi:10.1056/nejm198204223061603 · Cited by 199
Drug-Related Information Generates Placebo and Nocebo Responses That Modify the Drug Response
Flaten, M. A., Simonsen, T., & Olsen, H. (1999) · Psychosomatic Medicine · doi:10.1097/00006842-199903000-00018 · Cited by 190
Antidepressant Pharmacotherapy in the Treatment of Depression in the Very Old: A Randomized, Placebo-Controlled Trial
Roose, S. P., Sackeïm, H. A., Krishnan, K., Pollock, B. G., Alexopoulos, G. S., Lavretsky, H., Katz, I. R., Hakkarainen, H., & Old-Old Depression Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2050 · Cited by 189
Fluoxetine in Children and Adolescents With OCD: A Placebo-Controlled Trial
Liebowitz, M. R., Turner, S. M., Piacentini, J. C., Beidel, D. C., Clarvit, S. R., Davies, S. O., Graae, F., Jaffer, M., Lin, S., Sallee, F. R., et al. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200212000-00014 · Cited by 186
Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder
Montgomery, S., Kasper, S. F., Stein, D. J., Hedegaard, K. B., & Lemming, O. M. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200103000-00002 · Cited by 185
Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
Fabre, L. F., Abuzzahab, F. S., Amin, M., Claghorn, J. L., MENDELS, J., Petrie, W. M., Dubé, S., & Small, J. G. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00178-8 · Cited by 184
Side-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data
Brambilla, P., Cipriani, A., Hotopf, M., & Barbui, C. (2005) · Pharmacopsychiatry · doi:10.1055/s-2005-837806 · Cited by 181
Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose study
Davidson, J. R. T., Bose, A., Korotzer, A. R., & Zheng, H. (2004) · Depression and Anxiety · doi:10.1002/da.10146 · Cited by 179
A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease
Petracca, G., Tesón, A., Chemerinski, E., Leiguarda, R. C., & STARKSTEIN, S. E. (1996) · Journal of Neuropsychiatry · doi:10.1176/jnp.8.3.270 · Cited by 174
A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder
Montgomery, S. A. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90266-o · Cited by 172
Multicenter, Placebo-Controlled, Fixed-Dose Study of Citalopram in Moderate-to-Severe Depression
Feighner, J. P., & Overø, K. F. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1204 · Cited by 169
Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects
Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.2.155 · Cited by 167
Self-citation
A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory
Jenike, M. A., Hyman, S. E., Baer, L., Holland, A. J., Minichiello, W. E., Buttolph, L., D, P. S. M., Seymour, R., & Ricciardi, J. N. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.9.1209 · Cited by 165
An 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression
Schneider, L. S. S., Nelson, J. C., Clary, C. M., NEWHOUSE, P. A., Krishnan, K., Shiovitz, T. M., Weihs, K. L., & the Sertraline Elderly Depression Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1277 · Cited by 165
Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study: Research Article: Escitalopram in Long-Term Treatment of SAD
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Acute and Long-Term Treatment and Prevention of Relapse of Obsessive-Compulsive Disorder With Paroxetine
Hollander, E., Allen, A., Steiner, M., Wheadon, D. E., Oakes, R., Burnham, D. B., & Paroxetine OCD Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0919 · Cited by 156
Comparative Risk for Harms of Second-Generation Antidepressants: A Systematic Review and Meta-Analysis
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients With Alzheimer’s Disease
Petracca, G., Chemerinski, E., & STARKSTEIN, S. E. (2001) · International Psychogeriatrics · doi:10.1017/s104161020100761x · Cited by 148
Sertraline in the Treatment of Panic Disorder
Pollack, M. H., Otto, M. W., Worthington, J. J., Manfro, G. G., & Wolkow, R. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.11.1010 · Cited by 143
Sertraline in the treatment of panic disorder
Londborg, P. D., Wolkow, R., Smith, W. T., DuBoff, E., England, D., Ferguson, J. M., Rosenthal, M. H., & Weise, C. C. (1998) · The British Journal of Psychiatry · doi:10.1192/bjp.173.1.54 · Cited by 142
A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression
Tollefson, G. D., Bosomworth, J. C., Heiligenstein, J. H., Potvin, J. H., & Holman, S. (1995) · International Psychogeriatrics · doi:10.1017/s1041610295001888 · Cited by 142
Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design.
Geller, B., Cooper, T. B., Graham, D. L., Marsteller, F. A., & Bryant, D. M. (1989) · PubMed · Cited by 142
Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group.
Justice, A. C., Rabeneck, L., Hays, R. D., Wu, A. W., & Bozzette, S. A. (1999) · PubMed · Cited by 141
A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia
Hellerstein, D. J., Yanowitch, P., Rosenthal, J., Samstag, L. W., Maurer, M., Kasch, K. L., Burrows, L., Poster, M., Cantillon, M., & Winston, A. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1169 · Cited by 141
Escitalopram in the Treatment of Panic Disorder
Stahl, S. M., Gergel, I. P., & Li, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1107 · Cited by 140
Efficacy of Sertraline in a 12-Week Trial for Generalized Anxiety Disorder
Allgulander, C., Dahl, A. A., Austin, C., Morris, P., Søgaard, J., Fayyad, R. S., Kutcher, S., & Clary, C. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1642 · Cited by 140
Cortical correlates of false expectations during pain intensity judgments—a possible manifestation of placebo/nocebo cognitions
Lorenz, J., Hauck, M., Paur, R. C., Nakamura, Y., Zimmermann, R., Bromm, B., & Engel, A. K. (2005) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2005.03.010 · Cited by 138
Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.
Chouinard, G., Goodman, W. K., Greist, J. H., Jenike, M. A., Rasmussen, S., White, K., Hackett, E., Gaffney, M., & Bick, P. A. (1990) · PubMed · Cited by 136
Paroxetine Treatment in Children and Adolescents With Major Depressive Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
Emslie, G. J., Wagner, K. D., Kutcher, S., Krulewicz, S., Fong, R., CARPENTER, D. J., Lipschitz, A., Machin, A., & Wilkinson, C. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000214189.73240.63 · Cited by 136
Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study
Stein, D. J., Andersen, E. W., Tonnoir, B., & Fineberg, N. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178838 · Cited by 134
Fluoxetine in Depressed Patients on Dialysis
Blumenfield, M., Levy, N. B., Spinowitz, B., Charytan, C., Beasley, C. M., Dubey, A. K., Solomon, R., Todd, R., Goodman, A. I., & Bergstrom, R. F. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/wq33-m54t-xn7l-v8mx · Cited by 133
Sertraline in the Treatment of Panic Disorder: A Double-Blind Multicenter Trial
Pohl, R. B., Wolkow, R., & Clary, C. M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1189 · Cited by 133
Physician Response to Patient Reports of Adverse Drug Effects
Golomb, B. A., McGraw, J. J., Evans, M. A., & Dimsdale, J. E. (2007) · Drug Safety · doi:10.2165/00002018-200730080-00003 · Cited by 131
Efficacy and Tolerability of Paroxetine for the Long-Term Treatment of Generalized Anxiety Disorder
Stocchi, F., Nordera, G., Jokinen, R., Lepola, U. M., Hewett, K., Bryson, H., Iyengar, M. K., & Paroxetine Generalized Anxiety Disorder Study Team (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0305 · Cited by 128
Escitalopram in the treatment of social anxiety disorder
Kasper, S. F., Stein, D. J., Loft, H., & Nil, R. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.186.3.222 · Cited by 126
Escitalopram in the Treatment of Depressed Elderly Patients
Kasper, S. F., de Swart, H., & Andersen, H. F. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.10.884 · Cited by 124
Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial
Lenze, E. J., Mulsant, B. H., Shear, M. K., Dew, M. A., Miller, M. D., Pollock, B. G., Houck, P., Tracey, B., & Reynolds, C. F. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.146 · Cited by 122
Fixed-dose fluoxetine therapy for depression.
Jf, W., Dunlop, S. R., Dornseif, B. E., & Zerbe, R. L. (1987) · PubMed · Cited by 120
Treatment of obsessive—compulsive disorder with fluvoxamine
Goodman, W. K., Kozak, M., Liebowitz, M. R., & White, K. L. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00003 · Cited by 120
Response to Desipramine Treatment in Adolescent Depression: A Fixed-Dose, Placebo-Controlled Trial
Kutcher, S., Boulos, C., Ward, B., Marton, P., SIMEON, J. G., Ferguson, H. B., Szalai, J. P., KATIC, M., Roberts, N., Dubois, C., et al. (1994) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199406000-00010 · Cited by 118
Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials
Goodman, W. K., Bose, A., & Wang, Q. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.11.011 · Cited by 117
A Randomized, Double-Blind, Fixed-Dose Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Anxiety Disorder
Liebowitz, M. R., Stein, M. B., Tancer, M. E., Carpenter, D. J., Oakes, R., & Pitts, C. D. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0113 · Cited by 117
Double-Blind Comparison of Sertraline and Placebo in Stroke Patients With Minor Depression and Less Severe Major Depression
Murray, V., von Arbin, M., Bartfai, A., Berggren, A.-L., Landtblom, A., Lundmark, J., Näsman, P., Olsson, J., Samuelsson, M., Terént, A., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0606 · Cited by 115
Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Effect of Fluvoxamine on Panic Disorder
Hoehn‐Saric, R., McLeod, D. R., & Hipsley, P. A. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199310000-00004 · Cited by 112
A Randomized, Double-blind, Placebo-controlled Study of Citalopram in Adolescents With Major Depressive Disorder
von Knorring, A.-L., Olsson, G. I., Thomsen, P. H., Lemming, O. M., & Hultén, A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000219051.40632.d5 · Cited by 111
Treatment of Major Depression in HIV-Seropositive Men
Zisook, S., Peterkin, J. J., Goggin, K. J., Sledge, P., Atkinson, J. H., & Grant, I. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0502 · Cited by 110
Intravenous Clomipramine for Obsessive-Compulsive Disorder Refractory to Oral Clomipramine
Fallon, B. A., Liebowitz, M. R., Campeas, R. B., Schneier, F. R., Marshall, R. D., Davies, S. O., Goetz, D., & Klein, D. F. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.10.918 · Cited by 110
A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta‐analysis
Wilson, K., & Mottram, P. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1156 · Cited by 107
Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial
Paile‐Hyvärinen, M., Wahlbeck, K., & Eriksson, J. G. (2003) · BMC Family Practice · doi:10.1186/1471-2296-4-7 · Cited by 106
Placebo and Nocebo Responses, Cortisol, and Circulating Beta-Endorphin
Johansen, O., Brox, J. H., & Flaten, M. A. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000082626.56217.cf · Cited by 105
Effect of Treating Depression on Quality-of-Life and Exercise Tolerance in Severe COPD
Eiser, N. M., Harte, R., Karvounis, S., Phillips, C., & Isaac, M. T. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-57596 · Cited by 105
Fluoxetine in Social Phobia: A Double-Blind, Placebo-Controlled Pilot Study
Kobak, K. A., Greist, J. H., Jefferson, J. W., & Katzelnick, D. J. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00005 · Cited by 103
A Twelve-Week, Double-Blind, Randomized Comparison of Nortriptyline and Paroxetine in Older Depressed Inpatients and Outpatients
Mulsant, B. H., Pollock, B. G., Nebes, R. D., Miller, M. D., Sweet, R. A., Stack, J., Houck, P. R., Bensasi, S., Mazumdar, S., & Reynolds, C. F. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00009 · Cited by 103
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Controlled-Release Fluvoxamine in Patients With Obsessive-Compulsive Disorder
Hollander, E., Koran, L. M., Goodman, W. K., Greist, J. H., Ninan, P. T., Yang, H., Li, D., & Barbato, L. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0604 · Cited by 103
An International, Multicenter, Placebo-Controlled Trial of Paroxetine in Adolescents with Major Depressive Disorder
Berard, R. M. F., Fong, R., Carpenter, D. J., Thomason, C., & Wilkinson, C. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.59 · Cited by 102
Low-dose fluoxetine therapy for depression.
Wernicke, J. F., Dunlop, S. R., Dornseif, B. E., Bosomworth, J. C., & Humbert, M. (1988) · PubMed · Cited by 101
Efficacy and Tolerability of Controlled-Release and Immediate-Release Paroxetine in the Treatment of Depression
Golden, R. N., Nemeroff, C. B., McSorley, P., Pitts, C. D., & Dube, E. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0707 · Cited by 101
Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Modigh, K., Westberg, P., & Eriksson, E. (1992) · PubMed · Cited by 100
A Randomized Trial of Citalopram versus Placebo in Outpatients with Asthma and Major Depressive Disorder: A Proof of Concept Study
Brown, E. S., Vigil, L., Khan, D. A., Liggin, J. D. M., Carmody, T. J., & Rush, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.030 · Cited by 99
Efficacy of Sertraline in Severe Generalized Social Anxiety Disorder
Liebowitz, M. R., DeMartinis, N. A., Weihs, K. L., Londborg, P. D., Smith, W. T., Chung, H., Fayyad, R. S., & Clary, C. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0708 · Cited by 96
Endogenous opiates and the placebo effect
Sauro, M. D., & Greenberg, R. P. (2005) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2004.07.001 · Cited by 94
Comparison of the tolerability and efficacy of citalopram and??amitriptyline in elderly depressed patients treated in general practice
Kyle, C. J., Petersen, H. E. H., & Over�, K. F. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)8:4 · Cited by 94
Superiority of Clomipramine over Imipramine in the
Modigh, K., Westberg, P., & Eriksson, E. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199208000-00007 · Cited by 92
Fluoxetine in posttraumatic stress disorder.
van der Kolk, B. A., Dreyfuss, D. A., Michaels, M. J., Shera, D., Berkowitz, R., Fisler, R. E., & Saxe, G. (1994) · PubMed · Cited by 92
Efficacy, Safety, and Tolerability of Sertraline in Patients with Late‐Life Depression and Comorbid Medical Illness
Sheikh, J. I., Cassidy‐Eagle, E. L., Doraiswamy, P. M., Salomon, R. M., Hornig, M., Holland, P. J., Mandel, F. S., Clary, C. M., & Burt, T. (2003) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52015.x · Cited by 91
Trimipramine in physical illness with depression.
Rifkin, A. E., Reardon, G. T., Siris, S. G., Karagji, B., Kim, Y. S., Hackstaff, L., & Endicott, N. A. (1985) · PubMed · Cited by 91
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions.
Liccardi, G., Senna, G., Russo, M. L., Bonadonna, R. C., Crivellaro, M., Dama, A., D’Amato, M., D’Amato, G., Canonica, G. W., & Passalacqua, G. (2004) · PubMed · Cited by 88
Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder
Sheehan, D. V., Burnham, D. B., Iyengar, M. K., Perera, P., & Paxil CR Panic Disorder Study Group (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0105 · Cited by 85
Placebo-Controlled, Multicenter Study of Sertraline Treatment for Obsessive-Compulsive Disorder
Kronig, M. H., Apter, J. T., Asnis, G. M., Bystritsky, A., Curtis, G., Ferguson, J. M., Landbloom, R. P., Munjack, D. J., Riesenberg, R. A., Robinson, D. G., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00013 · Cited by 84
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression
D, M. F. M., Amsterdam, J. D., Deltito, J. A., Salzman, C., Schwaller, M., & Dünner, D. L. (1998) · Annals of Clinical Psychiatry · doi:10.1023/a:1022337927842 · Cited by 82
A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder
Moscovitch, A., Blashko, C. A., Eagles, J., DARCOURT, G., Thompson, C., Kasper, S. F., & Lane, R. M. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1594-8 · Cited by 82
Screening of dementia in community-dwelling elderly through informant report
Morales, J., Bermejo, F., Romero, M., & Del-Ser, T. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199708)12:8 · Cited by 81
A placebo-controlled trial of paroxetine in the treatment of major depression.
Smith, W. T., & Glaudin, V. (1992) · PubMed · Cited by 80
Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial
Martényi, F., & Soldatenkova, V. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.10.007 · Cited by 79
Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients
Jenike, M. A., Baer, L., D, P. S. M., Weilburg, J. B., Holland, A. J., & Seymour, R. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.10.1328 · Cited by 79
Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients
Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D. W., Jameel, M., Desagani, K., & Woods, S. W. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00265-7 · Cited by 76
A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder
Westenberg, H. G. M., Stein, D. J., Yang, H., Li, D., & Barbato, L. M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104906.75206.8b · Cited by 73
Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo [published erratum appears in Am J Psychiatry 1990 Oct;147(10):1393]
Jenike, M. A., Baer, L., D, P. S. M., Minichiello, W. E., Holland, A. J., & Seymour, R. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.7.923 · Cited by 73
Sertraline Treatment for Generalized Anxiety Disorder
Brawman‐Mintzer, O., Knapp, R. G., Rynn, M. A., Carter, R. E., & Rickels, K. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0603 · Cited by 72
Stroke, vascular risk factors and depression
Stewart, R. J., Prince, M. J., Richards, M., Brayne, C., & MANN, A. H. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.1.23 · Cited by 71
Fluvoxamine-Controlled Release Formulation for the Treatment of Generalized Social Anxiety Disorder
Davidson, J. R. T., Yaryura-Tobias, J. A., DuPont, R. L., Stallings, L., Barbato, L. M., van der Hoop, R. G., & Li, D. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106222.36344.96 · Cited by 69
The Additive Impact of Anxiety and a Placebo on Pain
Staats, P. S., Staats, A. W., & Hekmat, H. M. (2001) · Pain Medicine · doi:10.1046/j.1526-4637.2001.01046.x · Cited by 69
Clomipramine Treatment of Agoraphobic Women
Johnston, D. G. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800290073009 · Cited by 68
Controlled-Release Paroxetine in the Treatment of Patients With Social Anxiety Disorder
Lepola, U. M., Bergtholdt, B., Lambert, J. S., Davy, K., & Ruggiero, L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0213 · Cited by 66
Psychopharmacological treatment of social phobia.
Liebowitz, M. R., Gorman, J., Fyer, A. J., Campeas, R. B., Levin, A. P., Davies, S., & Df, K. (1985) · PubMed · Cited by 66
Controlled efficacy study of fluoxetine in dysthymia
Vanelle, J., Attar-Levy, D., Poirier, M. F., Bouhassira, M., Blin, P., & Olié, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.4.345 · Cited by 65
Notes for a Critical Personality Psychology: Making Room under the Critical Psychology Umbrella
Ouellette, S. C. (2007) · Social and Personality Psychology Compass · doi:10.1111/j.1751-9004.2007.00039.x · Cited by 63
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression
Fava, M., Amsterdam, J. D., Deltito, J. A., et al. (1998) · Annals of Clinical Psychiatry · doi:10.3109/10401239809147030 · Cited by 63
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: Randomised, placebo-controlled trial
Michelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62 · cited 1×
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
Background
A placebo‐controlled, double‐blind, clinical trial of paroxetine in depressed outpatients
Rickels, K., Amsterdam, J. D., Clary, C. M., Fox, I., Schweizer, E. E., & Weise, C. C. (1989) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1989.tb07188.x · Cited by 59
Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression.
Dunlop, S. R., Dornseif, B. E., Wernicke, J., & Potvin, J. H. (1990) · PubMed · Cited by 59
Effectiveness of Low Doses of Paroxetine Controlled Release in the Treatment of Major Depressive Disorder
Trivedi, M. H., Pigott, T. A., Perera, P., Dillingham, K., Carfagno, M. L., & Pitts, C. D. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1010 · Cited by 58
Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
Greist, J. H., Jefferson, J. W., Rosenfeld, R., Gutzmann, L. D., March, J. S., & Barklage, N. E. (1990) · PubMed · Cited by 58
Double-blind placebo-controlled pilot study of paroxetine for specific phobia
Benjamin, J., Ben-Zion, I. Z., Karbofsky, E., & Dannon, P. N. (2000) · Psychopharmacology · doi:10.1007/s002130000372 · Cited by 56
The Effects of Manipulating Expectations Through Placebo and Nocebo Administration on Gastric Tachyarrhythmia and Motion-Induced Nausea
Levine, M. E., Stern, R. M., & Koch, K. L. (2006) · Psychosomatic Medicine · doi:10.1097/01.psy.0000221377.52036.50 · Cited by 53
Antidepressant prescription for depression in general practice in The Netherlands.
van Marwijk, H., Bijl, D., r, H. J. A., & de Haan, M. (2001) · Pharmacy World & Science · doi:10.1023/a:1011294305606 · Cited by 51
Can Physiologic Assessment and Side Effects Tease Out Differences in PTSD Trials? A Double-Blind Comparison of Citalopram, Sertraline, and Placebo
Tucker, P. M., MD, Potter-Kimball, R., RN, MS, Wyatt, D. B., Masters, B., Parker, D. E., PhD, Burgin, C. E., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4179 · Cited by 49
Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial
Stein, D. J., Westenberg, H. G. M., Yang, H., Li, D., & Barbato, L. M. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570300364x · Cited by 48
Treatment of Dysthymia With Sertraline
Ravindran, A. V., Guelfi, J. D., Lane, R. M., & Cassano, G. B. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1103 · Cited by 47
The Oral Dose-Effect Relationship for Fluvoxamine: a Fixed-Dose Comparison Against Placebo in Depressed Outpatients
Walczak, D. D., Apter, J. T., Halikas, J. A., Borison, R. L., Carman, J. S., Post, G., PATRICK, R. O., Cohn, J. N., Cunningham, L. A., Rittberg, B. R., et al. (1996) · Annals of Clinical Psychiatry · doi:10.3109/10401239609147751 · Cited by 47
Paroxetine versus placebo: a double-blind comparison in depressed patients.
Claghorn, J. L., Kiev, A., Rickels, K., Smith, W. T., & Dunbar, G. C. (1992) · PubMed · Cited by 45
A double-blind, placebo-controlled dose-finding study with sertraline.
Amin, M., Lehmann, H., & Mirmiran, J. (1989) · PubMed · Cited by 42
Short- and Long-Term Treatment of Obsessive-Compulsive Disorder with Fluvoxamine
Mallya, G. K., White, K., WATERNAUX, C. M., & Quay, S. (1992) · Annals of Clinical Psychiatry · doi:10.3109/10401239209150443 · Cited by 41
The Power of Expectation – Understanding the Placebo and Nocebo Phenomenon
Rief, W., Hofmann, S. G., & Nestoriuc, Y. (2008) · Social and Personality Psychology Compass · doi:10.1111/j.1751-9004.2008.00121.x · Cited by 40
Self-citation
Fluoxetine versus other types of pharmacotherapy for depression (Review)
Cipriani, A., Brambilla, P., Furukawa, T. A., Geddes, J. R., Gregis, M., Hotopf, M. H., Malvini, L., & Barbui, C. (2005) · Cited by 39
A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia
Heiligenstein, J. H., Tollefson, G. D., & Faries, D. E. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300840-00007 · Cited by 38
Assessment of Adverse Events Associated With Triptans—Methods of Assessment Influence the Results
Sheftell, F. D., Feleppa, M., Tepper, S. J., Rapoport, A. M., Ciannella, L., & BIGAL, M. E. (2004) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04191.x · Cited by 38
A double-blind, placebo-controlled study of paroxetine in depressed outpatients.
Kiev, A. (1992) · PubMed · Cited by 36
Paroxetine in the treatment of obsessive‐compulsive disorder: randomized, double‐blind, placebo‐controlled study in Japanese patients
Kamijima, K., Murasaki, M., Asai, M., Higuchi, T., Nakajima, T., Taga, C., & Matsunaga, H. (2004) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2004.01278.x · Cited by 35
The effect of low dose lofepramine in depressed elderly patients in general medical wards.
Tan, R., Barlow, R., Abel, C., Reddy, S., Palmer, A. J., Fletcher, A., Nicholl, C., Bm, P., & Bulpitt, C. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04284.x · Cited by 33
The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies
Sheikh, J. I., Londborg, P. D., Clary, C. M., & Fayyad, R. S. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015060-00004 · Cited by 33
A double blind comparison of lofepramine, imipramine and placebo in patients with primary depression
Feighner, J. P., Meridith, C. H., and, J. E. D., & HENDRICKSON, G. G. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00918.x · Cited by 26
Placebo/Nocebo Symptom Reporting in a Sham Herbal Supplement Trial
Link, J., Haggard, R., Kelly, K. S., & Forrer, D. (2006) · Evaluation & the Health Professions · doi:10.1177/0163278706293403 · Cited by 24
Sex-related differences in nortriptyline-induced side-effects among depressed patients
Pomara, N., Shao, B., Choi, S. J., Tun, H., & Suckow, R. F. (2001) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00175-0 · Cited by 21
Who controls the placebo? Introducing a Placebo Quality Checklist for pharmacological trials
Brinkhaus, B., Pach, D., Lüdtke, R., & Willich, S. N. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.06.005 · Cited by 16
Placebo‐Controlled trial of paroxetine in depressive illness
Edwards, J. G., & Goldie, A. (1993) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470080306 · Cited by 14
Untitled work
(1994) · PubMed · Cited by 10
Do hypnotic analgesic interventions contain placebo effects?
Price, D. (2006) · Pain · doi:10.1016/j.pain.2006.04.021 · Cited by 10
Depressed patients who suicide at their first attempt have had few admissions
Roy, A. (1999) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1999)9:2 · Cited by 6
Placebo-Associated Blood Pressure Response and Adverse Effects in the Treatment of Hypertension
Preston, R. A., Materson, B. J., Reda, D. J., & Williams, D. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1449 · Cited by 2
Untitled work
Emslie (1998) · doi:10.1002/(sici)1520-6394(1998)7:1

Research works printed but not linked: 22

Cipriani, 2005, Cochrane Database Syst Rev, &NA;, CD004185
Liccardi, 2004, J Investig Allergol Clin Immunol, 14, 104
Chouinard, 1990, Psychopharmacol Bull, 26, 279
Claghorn, 1992, J Clin Psychiatry, 53, 434
Dunlop, 1990, Psychopharmacol Bull, 26, 173
Fabre, 1985 Jan, Curr Ther Res, 37, 115
Ferguson, 1994, J Clin Psychiatry, 55, 258
Geller, 1990, Psychopharmacol Bull, 26, 85
Greist, 1990, J Clin Psychiatry, 51, 292
Kasper, 2005, Am J Geriatr Psychiatry, 13, 884, 10.1097/00019442-200510000-00008 · DOI
Kiev, 1992, J Clin Psychiatry, 53, 27
Lepola, 2003 Jul, Int Clin Psychopharmacol, 18, 211, 10.1097/00004850-200307000-00003 · DOI · Paper page
Rickels, 1986 Apr, Curr Ther Res, 39, 559
Rifkin, 1985, J Clin Psychiatry, 46, 4
Smith, 1992 Feb, J Clin Psychiatry, 53, 36
Tucker, 2003, Psychopharmacol Bull, 37, 135
van der Kolk, 1994 Dec, J Clin Psychiatry, 55, 517
Wernicke, 1988, Psychopharmacol Bull, 24, 183
Wernicke, 1987, Psychopharmacol Bull, 23, 164
Amin, 1989, Psychopharmacol Bull, 25, 164
Trindade, 1998, CMAJ, 159, 1245
Justice, 1999, J Acquir Immune Defic Syndr, 21, 126

Sorted by citations

The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Self-citation
Placebo and the New Physiology of the Doctor-Patient Relationship
Benedetti, F. (2013) · Physiological Reviews · doi:10.1152/physrev.00043.2012 · Cited by 492
Effects of empathic and positive communication in healthcare consultations: a systematic review and meta-analysis
Howick, J., Moscrop, A., Mebius, A., Fanshawe, T. R., Lewith, G. T., Bishop, F. L., Mistiaen, P., Roberts, N. W., Dieninytė, E., Hu, X.-Y. M., et al. (2018) · Journal of the Royal Society of Medicine · doi:10.1177/0141076818769477 · Cited by 472
The Nocebo Effect and Its Relevance for Clinical Practice
Colloca, L., & Miller, F. G. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182294a50 · Cited by 454
Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
Self-citation

See all 202

Authors: Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J.
Affiliations: Philipps University of Marburg (DE)
Boston University (US)
Brigham and Women's Hospital (US)
Corresponding author: Rief, Winfried
ORCID: Rief, Winfried
Nestoriuc, Yvonne
Dogan, Imis
Schreiber, Franziska
Hofmann, Stefan G.
Avorn, Jerry
Venue: Drug Safety
Publisher: Springer Science and Business Media LLC
Published: 2009-11
Volume: 32
Issue: 11
Pages: 1041-1056
ISSN: 0114-5916 (ISSN-L)
DOI: 10.2165/11316580-000000000-00000
OpenAlex: W59643826
Semantic Scholar: 50b250c59bddc89685a35b4cffa7ab9cf1b7a1e4
Cited by: 202
References: 192
Citations by year: 2026: 3 · 2025: 6 · 2024: 11 · 2023: 6 · 2022: 15 · 2021: 14 · 2020: 12 · 2019: 18 · 2018: 16 · 2017: 11 · 2016: 17 · 2015: 15 · 2014: 16 · 2013: 11 · 2012: 16
FWCI: 12.82
Type: journal article
Language: en
Open access: closed
Locations: Drug Safety (publishedVersion)
PubMed (publishedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Topics: Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: placebo group, selective serotonin reuptake inhibitors, tricyclic antidepressants, investigator bias, xerostomia, sleepiness, constipation, sexual dysfunction, antidepressant trials
MeSH terms: Antidepressive Agents, Tricyclic, Humans, Regression Analysis, Research Personnel, Bias, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Research Subjects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials: A Systematic Review and Meta-Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks